[Mercaptopurine and silylated mercaptopurine the treatment of experimental allergic encephalomyelitis].
The therapeutic effects of mercaptopurine (6-mercaptopurine, 6-MP) and a silylated derivative (6-trimethylsilylthio-9-trimethyl-silylpurine, S-MP) were compared on the course of T lymphocyte line mediated experimental allergic encephalomyelitis (t-EAE). This transferred EAE is a passively induced model disease in Lewis rats easy to elicit, reliably reproducible and characterized by a dose-dependent lethality. If given at different points in single injections the silicon derivative is shown to be more efficient than 6-MP (43/125 surviving animals compared to 26/129), severity of disease is attenuated and number of survivors increased. Silylation is able to improve blood-brain barrier and cellular permeability; S-MP suppresses intrathecal inflammatory cells more effectively than the original immunosuppressant.
Vohl
M L
ML
Neurologische Universitätsklinik Würzburg.
Westarp
M E
ME
Wekerle
H
H
Gerlach
M
M
Jutzi
P
P
Przuntek
H
H
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D001812:Blood-Brain Barrier / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000187:drug effects; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D005260:Female; D015122:Mercaptopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012825:Silicon / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D014297:Trimethylsilyl Compounds / Q000627:therapeutic use*
D014297:Trimethylsilyl Compounds; C063925:6-trimethylsilylthio-9-trimethylsilylpurine; D015122:Mercaptopurine; D012825:Silicon
Mercaptopurin und silyliertes Mercaptopurin in der Behandlung der experimentell allergischen Enzephalomyelitis.